You are here

SBIR Phase II: Development of Novel Dendrimer-based Technologies for Phosphorylation Analyses

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 1256600
Agency Tracking Number: 1256600
Amount: $500,000.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: BC
Solicitation Number: N/A
Solicitation Year: 2012
Award Year: 2013
Award Start Date (Proposal Award Date): 2013-02-15
Award End Date (Contract End Date): 2015-01-31
Small Business Information
1281 Win Hentschel Blvd.
West Lafayette, IN 47906-4182
United States
DUNS: 965433258
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Anton Iliuk
 (765) 490-6834
Business Contact
 Anton Iliuk
Phone: (765) 490-6834
Research Institution

This Small Business Innovation Research (SBIR) Phase II project addresses the unmet needs for effective analysis of protein phosphorylation, a process where a phosphate group is added to a protein to change its function. Protein phosphorylation is a crucial modification of proteins; its abnormalities have been implicated in many diseases. Therefore, assessing the phosphorylation status of individual proteins or classes of proteins, qualitatively or quantitatively, has become a routine but extremely important step in the majority of life science research labs. Existing technologies have glaring deficiencies, including low reproducibility, poor recovery, high cost, reduced selectivity and prolonged experiment time. The platform technology to be developed during this Phase II project will greatly alleviate these shortcomings by providing lucrative, general approaches for phosphorylation analyses. The technologies will enable general phosphorylation detection, cost-effective cancer inhibitor screenings, and kinase/phosphatase activity quantitation for new drug discovery. The broader impact/commercial potential of this project is the development of platform technology to improve a set of biochemical assays, thus enabling the discovery of new therapeutic targets and drugs. Protein phosphorylation and kinase inhibitors as drug targets are currently at the peak of research and development (R & D), responsible for over 30% of the total drug discovery expenses. These R & D activities could greatly benefit from the proposed technologies due to their innovative design and versatile features for optimum efficiency, and the ability to reproducibly explore phosphorylation events in unprecedented depth. These should provide invaluable tools and address needs of many bioscience research labs/facilities in academic and industrial settings.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government